Chris Bai, Ph.D.

Chairman

Dr. Bai provides the direction and instrumental advice to discovering and developing peptide drugs. He also has rich experience in founding, growing and managing biopharmaceutical companies. He founded Ambio a specialty pharma company in 2012, and AmbioPharm one of the global peptide CDMOs in 2007. He had also served as President and CEO of American Peptide Company and Senior R&D scientist at Abbott Laboratories in his earlier career.

Rob Hughes, CPA, MBA

Chief Financial Officer 

Mr. Hughes is an accomplished financial executive with over 25 years of experience, with considerable experience in building and guiding small, growing life science companies. He brings an in-depth understanding of corporate finance and has expertise in strategic planning, fund raising, financial analysis and reporting, mergers and acquisitions, budgeting and risk management. Prior to Ambio, he held leadership roles at Stridebio, Selentity Therapeutics and Viamet Pharmaceuticals. Mr. Hughes is a CPA and holds a B.S. from the University of Maryland, where he double majored in Finance and Accounting. He also holds an MBA from the University of North Carolina.

Simrat Singh, Ph.D.

Chief Operating Officer

As a Chief Operating Officer of Ampeptec, Inc., Dr. Singh is responsible for overall operations of the company. He holds a M.S. degree in Organic Chemistry and Ph.D. in Analytical Chemistry from Florida International University. He has over 15 years of experience in the GLP’s (Glucagon Like Peptide’s) and diabetes space. He has been involved in the development and regulatory approval of multiple complex peptides including GLP-1’s globally. He brings an in-depth knowledge of GLP’s and insulin development as well as expertise in advanced characterization techniques. During his tenure in various roles, he has played a key role in the formulation development, scale-up, and technology transfer for commercial manufacturing of complex peptides including GLP’s. He has been extensively involved in developing and maintaining strategic relationships with various investment groups as well as large pharmaceutical companies worldwide.

Andrei A. Purmal, Ph.D.

Head of Drug Development in USA

As a Sr. Director, Dr. Purmal is responsible for preclinical development and transition into the clinical stage of Ampeptec’s novel insulin and GLP-1 peptide analogs. He has over 25 years of experience in the pharmaceutical industry and brings in-depth understanding of drug discovery, preclinical, CMC, and analytical development to support IND submissions and Phase 1-3 clinical trials. As a principal technical expert, he has led multidisciplinary product development programs related to small molecules, proteins, and peptides. Several new chemical entities developed by Dr. Purmal and his colleagues reached the clinical phase. He holds a Ph.D. in the chemistry of nucleic acids and proteins.

Fred Zhang, MBA

Head of Drug Development in China

As a head of Drug Development in China, Mr. Zhang is responsible for organizing and coordinating the R&D activities in China. He has over 22 years of experience in R&D and regulatory affairs in the pharmaceutical industry. He possesses a deep understanding of drug development and regulatory affairs. Throughout his career, he has played a pivotal role in guiding projects from R&D to launch, with expertise spanning small molecules, antibodies, and peptides.

He is a licensed pharmacist, and holds a Pharmacy B.S. from Jiangxi University of Chinese Medicine and an MBA from Suzhou University.